The effect of a 6-month ketogenic medium-chain triglyceride supplement on plasma cardiometabolic and inflammatory markers in mild cognitive impairment.

•Ketogenic medium-chain triglycerides (kMCT) have been shown to improve cognition in mild cognitive impairment.•The long-term effect of kMCT on cardiometabolic and peripheral inflammatory profiles of individuals with mild cognitive impairment is still unknown.•When compared to an energy-matched placebo, 30 gs of kMCT/day taken for six months and up to 2-hour before post-intervention testing increased interleukin 8.•In the absence of significant changes in most cardiometabolic and peripheral inflammatory markers the clinical significance of this change remains to be determined.